The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer

Niklas Klümper; Viktor Grünwald; Arndt Hartmann; Michael Hölzel; Markus Eckstein

doi:10.1016/j.eururo.2024.04.026

The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer

Eur Urol. 2024 Nov;86(5):388-390. doi: 10.1016/j.eururo.2024.04.026. Epub 2024 May 13.

Authors

Niklas Klümper¹, Viktor Grünwald², Arndt Hartmann³, Michael Hölzel⁴, Markus Eckstein³

Affiliations

¹ Department of Urology, University Hospital Bonn, Bonn, Germany; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf, Bonn, Germany; Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany. Electronic address: [email protected].
² Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, Essen University Hospital, Essen, Germany.
³ Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; EMN Comprehensive Cancer Center, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research, Munich, Germany.
⁴ Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf, Bonn, Germany; Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany.

PMID: 38744632
DOI: 10.1016/j.eururo.2024.04.026

Abstract

Large trials of immune checkpoint inhibitors (ICIs) in castration-resistant prostate cancer (CRPC) have mostly failed. Biomarker-selected CRPC patients, especially those with high microsatellite instability (MSI-H), mismatch repair deficiency (dMMR), or elevated tumor mutational burden (TMB), may benefit from single-agent ICIs. Despite their rarity in CRPC (∼2-5%), identification of MSI-H, dMMR, or TMB-H could improve patient selection for immunotherapy.

Publication types

Editorial

MeSH terms

Biomarkers, Tumor* / genetics
DNA Mismatch Repair*
Humans
Immunotherapy* / methods
Male
Microsatellite Instability*
Mutation*
Predictive Value of Tests
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / genetics
Prostatic Neoplasms, Castration-Resistant* / pathology
Prostatic Neoplasms, Castration-Resistant* / therapy
Treatment Outcome

Substances

Biomarkers, Tumor